Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R
Clin Cancer Res. 2012 18 (2): 555-67

PMID: 22048237 · PMCID: PMC3549298 · DOI:10.1158/1078-0432.CCR-11-1491

MeSH Terms (24)

Adult Aged Aged, 80 and over Antineoplastic Agents, Alkylating Benzimidazoles Dacarbazine Disease-Free Survival DNA Mutational Analysis Drug Substitution Female Humans Kaplan-Meier Estimate Male MAP Kinase Kinase 1 MAP Kinase Kinase 2 Melanoma Middle Aged Mutation Neoplasm Staging Proto-Oncogene Proteins B-raf Proto-Oncogene Proteins p21(ras) Temozolomide Treatment Outcome Young Adult

Connections (1)

This publication is referenced by other Labnodes entities: